Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
|Articles|January 6, 2021
Supplements and Featured Publications
- Digital Supplement
- Volume 1
- Issue 1
Enhanced Recovery for Cesarean Deliveries in the United States: Perspectives From the Front Lines – Part 1
This article includes interviews with obstetrician-gynecologists on their experiences with enhanced recovery after surgery protocols for cesarean deliveries in the United States, including multimodal pain management and the use of long-lasting, nonopioid therapies.
Advertisement
Please see Part 2 of this educational supplement,
Articles in this issue
about 3 years ago
Focus on Pathways: Understanding and Treating Menopausealmost 4 years ago
Supplement: Closing the Gap in Cervical Cancer Screeningalmost 5 years ago
Advances in testing for preterm premature rupture of membranesalmost 5 years ago
Not all HPV genotypes pose same risk for diseaseabout 5 years ago
A New Treatment Option for Trichomoniasis: Single-Dose Secnidazoleover 5 years ago
Chlamydia Screening in the New Wave of COVID-19almost 6 years ago
Better for Women SeriesAdvertisement
Related to this article
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
Neurokinin receptor antagonists improve menopausal sleep disturbance
3
Brain fog at menopause: Separating normal change from dementia
4
Stephanie Faubion, MD, on the first menopause therapy discussion
5